He Took the Same Pill for 20 Years. Coming Off It Nearly Killed Him Faster Than Staying On Ever Would.

Matthew White took the same pill every day for over twenty years: 3 milligrams of lorazepam, prescribed, refilled, unremarkable. He is a pharmacist. He knew exactly what the drug was and exactly what it did, which is part of what makes his account, published in April on the Benzodiazepine Information Coalition’s site, so hard to wave off as a story about someone who didn’t understand what they were taking. He understood. He still ended up in an ambulance.

A benzodiazepine taper can be more dangerous than the drug itself was — and the addiction-treatment system, built almost entirely around illegal drugs, frequently doesn’t know what to do with a patient whose dependence started at a pharmacy counter.

If you’ve ever been handed a taper schedule by someone who has never watched a body go through this, you already know the gap between what’s written on the page and what actually happens to you.

What lorazepam was doing for twenty years, in plain terms

Benzodiazepines work by boosting the effect of GABA, the brain’s main “calm down” signal — which is why they’re so good, in the short term, at treating anxiety, insomnia, and seizures. Take one every day for months or years, though, and the brain adapts to that constant boost by quietly turning down its own natural calming system, the way a room stops looking bright once your eyes adjust to the light. Stop the drug suddenly after that adaptation has taken hold, and the brain is left running with its own dimmer switch stuck in the “off” position it built to compensate — which is what produces the two most dangerous features of benzodiazepine withdrawal: seizures and the kind of severe autonomic chaos that put White in an ambulance. Not craving in the pop-culture sense. A nervous system that has forgotten how to regulate itself without help.

White’s account describes exactly that cascade: seven days of inpatient medical detox, then a 30-day stay at a recovery center, during which he developed chest pain severe enough to require an ambulance, along with “high blood pressure, rapid heart rate, sweating, shaking, temperature fluctuations” — his nervous system’s control panel firing every alarm it had at once — and a stretch of what he calls “benzodiazepine-induced psychosis: confusion, disorientation, and difficulty distinguishing reality.” He is six months out now, working again, which he describes as a milestone he genuinely wasn’t sure he’d reach: he was “afraid I would not be able to continue working because my nervous system was still very much in turmoil.”

The system built for one kind of dependence, applied to another

Here’s where White’s account turns from a medical case study into an indictment of how care actually gets delivered. He entered a 30-day residential program built on the standard addiction-treatment model — the one designed, mostly, around illegal-drug dependence and a defined acute-withdrawal window of a week or two. Benzodiazepine withdrawal doesn’t reliably fit that window. Between 10% and 25% of chronic users experience what’s called protracted withdrawal, according to a peer-reviewed review of the clinical evidence — symptoms that persist for months or, in a minority of cases, years past the last dose, long after a 30-day program has discharged the patient and moved on. White reports medication errors during his stay and describes a program environment that, by his account, wasn’t built to recognize that a patient on a legitimate prescription tapering under medical care isn’t the same clinical picture as someone withdrawing from an illicit opioid, even though both deserve the same seriousness and the same care.

A 2022 peer-reviewed patient survey backs up the shape of his experience at scale, not just as an individual complaint: most respondents in that research described real difficulty and despair navigating tapering and discontinuation, while a smaller group described genuinely positive outcomes — including one person who reported major improvement after twenty years of disability tied to benzodiazepine use. The split matters. It means the doctors telling patients tapering is “generally safe” are not lying, and the patients describing it as one of the hardest things they’ve survived are not exaggerating. Both are describing the same drug, at different points on a wide range of individual response that the current system mostly isn’t built to predict in advance.

Both are describing the same drug, at different points on a wide range of individual response that the current system mostly isn’t built to predict in advance.

The part that should change how providers screen for this

There’s real news buried in the reassuring half of this story, and it’s worth stating plainly for anyone doing intake work: Columbia University researchers reported in March that benzodiazepine prescribing declined nationally between 2018 and 2022, with the steepest drop among adults 56 and older — exactly the population most vulnerable to the falls, cognitive impairment, and overdose risk that long-term benzodiazepine use carries. That’s the trend line moving the right direction. But the same research found that 42% of people currently prescribed a benzodiazepine are also taking another central-nervous-system depressant — most often an opioid or alcohol — in the same year, which is precisely the combination that turns a manageable dependence into a fatal one. A structured tapering review covering roughly 11,000 older adults across 30 studies found gradual, supervised discontinuation was generally safe and symptoms were typically mild and transient — which is true, and also not the experience White or the harder-hit respondents in that 2022 survey describe, because “generally safe” is a population-level finding, and the person in front of you in an intake appointment is not a population.

If you’re screening a new patient this week, the actionable version of that finding is simple: ask not just whether someone takes a benzodiazepine, but whether they’re also taking anything else that slows the nervous system down, because that co-prescription is where the risk concentrates — and ask before you write a taper schedule whether this specific patient’s history looks more like the 75-90% who taper without major incident, or more like the 10-25% for whom “protracted” means months, not weeks.

Where this drug has been before

This isn’t the first time American medicine has had to publicly reckon with a benzodiazepine problem it helped create. Diazepam — sold as Valium — became the best-selling prescription drug in the United States for most of the 1970s, prescribed so routinely to anxious, overwhelmed women that the Rolling Stones wrote a song about it, “Mother’s Little Helper,” years before the medical establishment caught up to what long-term use was doing to the people taking it. It took the better part of two decades, and a wave of dependence nobody had adequately warned patients about, before prescribing guidance shifted toward short-term use and real tapering protocols. We are, in a smaller and quieter way, having that same reckoning again now — this time about what happens on the way back down, not just about who gets prescribed the pill in the first place.

Six months into his own recovery, Matthew White is still working through what he calls a five-phase framework, and the thing he keeps returning to is a phrase he wants other patients to hear before they start a taper, not after: recovery from this is not linear, and needing more time than the pamphlet promised doesn’t mean you’re doing it wrong. If you are the one holding a taper schedule right now and it doesn’t match what your body is telling you, that gap is not a failure of your willpower. It’s a gap in a system that is only now, slowly, starting to take your kind of dependence as seriously as it takes the others.